KRAS and neoplasm: In recent years, molecular pathological features and gene mutations status (e.g., KRAS, BRAF, NRAS, TP53, microsatellite status, tumor mutation burden and immune checkpoint), and chemotherapy regimen have been shown to correlate with therapeutic response and survival outcomes [44, 45].